Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
NCT04564755
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
abrocitinib
Sponsor
Pfizer